Form 4: TransMedics Director Edwin Kania Receives RSU Grant

Director Edwin Kania acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Summary

• Director Edwin Kania was granted 2,922 restricted stock units (RSUs) on May 20, 2026.
• Each RSU represents a contingent right to receive one share of TransMedics Group, Inc. common stock.
• Following this transaction, the director's direct beneficial ownership increased to 263,732 shares.
• The director maintains an additional 46,142 shares held indirectly through the Kania 2021 GRAT B.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity ownership in a publicly traded company.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to align director incentives with long-term shareholder value creation in the medical technology sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-to-large cap medical device companies.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• Vesting of the granted restricted stock units according to the company's equity incentive plan.

Key Dates

Keywords

TransMedics, TMDX, Form 4, Insider Trading, Director Compensation, Equity Grant